公开(公告)号：US11603566B2

公开(公告)日：2023-03-14

申请号：US16322380

申请日：2017-08-04

申请人： BAYLOR RESEARCH INSTITUTE

发明人： Ajay Goel ,  Jinsei Miyoshi

IPC分类号： C12Q1/68 ,  C12Q1/6886 ,  A61P35/04 ,  A61K33/243 ,  A61K31/337 ,  A61K31/351 ,  A61K31/513 ,  C12Q1/02

摘要： The current disclosure relates to therapeutic treatments and diagnostic methods for esophageal cancer based on the expression level of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, said method comprising: diagnosing the patient with esophageal cancer when the patient is determined to have an elevated or decreased level of expression of one or more miRNAs selected from mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i in a sample from a patient relative to the expression level of the one or more miRNAs in a control sample; and administering an effective amount of an esophageal treatment to the diagnosed patient.

公开(公告)号：US11590189B2

公开(公告)日：2023-02-28

申请号：US16320257

申请日：2017-07-25

申请人： NATUREX S.A.

发明人： Pascale Elizabeth Renée Fança-Berthon ,  Leila Denise Falcao ,  Antoine Charles Bily ,  Marc Roller ,  Simona Birtic

IPC分类号： A61K36/63 ,  A23L33/105 ,  A61P1/16 ,  A61P3/04 ,  A61K9/00 ,  A61K31/351

摘要： The present invention relates to extracts from Fraxinus angustifolia samara, processes for providing such extracts, and methods and uses of the extracts obtained. In particular, the present invention relates to the use of such extracts in reversing obesity-related and/or metabolic syndrome-related gut microbiota dysbiosis treatment, treating or preventing hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and modulating and/or adjusting gut microbiota.

公开(公告)号：US20230051702A1

公开(公告)日：2023-02-16

申请号：US17977969

申请日：2022-10-31

申请人： Monir Elias

发明人： Monir Elias

IPC分类号： A61K31/366 ,  A61K31/198 ,  A61K31/351 ,  A61K36/906 ,  A23L2/395 ,  A61K36/67

摘要： A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.

公开(公告)号：US20230000816A1

公开(公告)日：2023-01-05

申请号：US17775029

申请日：2020-11-06

申请人： INCREVET, INC.

发明人： Michael HADD ,  Brian SEED ,  Thomas John DUPREE ,  Jordan MECHANIC

IPC分类号： A61K31/351 ,  A61K31/4965 ,  A61P13/12 ,  A61P9/04 ,  A61P3/10 ,  A61P9/12

摘要： Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

公开(公告)号：US11541028B2

公开(公告)日：2023-01-03

申请号：US16958597

申请日：2019-01-03

申请人： Mederis Diabetes LLC

发明人： John J Nestor

IPC分类号： A61K31/351 ,  A61P1/16 ,  A61P13/12 ,  A61K38/26 ,  A61K47/54 ,  A61K9/00 ,  A61K45/06

摘要： The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.

公开(公告)号：US20220401464A1

公开(公告)日：2022-12-22

申请号：US17822263

申请日：2022-08-25

申请人： VANDA PHARMACEUTICALS INC.

发明人： Mihael H. POLYMEROPOULOS ,  Louis William LICAMELE ,  Christian LAVEDAN

IPC分类号： A61K31/704 ,  A61K31/40 ,  A61K31/405 ,  A61K31/22 ,  A61K31/44 ,  A61K31/505 ,  A61K31/47 ,  A61K31/136 ,  A61K31/365 ,  A61K31/366 ,  A61K9/00 ,  A61K31/351

摘要： The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.

公开(公告)号：US20220387395A1

公开(公告)日：2022-12-08

申请号：US17631886

申请日：2020-07-27

申请人： Nurix Therapeutics, Inc.

发明人： Arthur T. SANDS ,  Neil F. BENCE ,  Christoph W. ZAPF ,  Frederick COHEN ,  Chenbo WANG ,  Thomas CUMMINS ,  Hiroko TANAKA ,  Morgan LAWRENZ ,  Mario CARDOZO ,  Dahlia WEISS ,  Jennifa GOSLING

IPC分类号： A61K31/4196 ,  C07D249/10 ,  C07D249/08 ,  C07D405/06 ,  C07D498/20 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04 ,  C07D498/04 ,  C07D401/14 ,  C07D471/20 ,  C07D487/04 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/10 ,  C07D491/107 ,  C07D487/10 ,  C07D498/10 ,  C07D417/12 ,  C07F5/02 ,  A61K38/17 ,  A61K35/17 ,  A61K39/395 ,  A61K31/704 ,  A61K31/427 ,  A61K31/407 ,  A61K38/14 ,  A61K31/473 ,  A61K31/7048 ,  A61K31/136 ,  A61K31/351 ,  A61K38/12 ,  A61K31/4995 ,  A61K31/337 ,  A61K38/08 ,  A61K31/437 ,  A61K31/439 ,  A61K31/7072 ,  A61K31/513 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/52 ,  A61K31/517 ,  A61K31/655 ,  A61K31/495 ,  A61K31/496 ,  A61K31/047 ,  A61K31/336 ,  A61K31/66 ,  A61K31/7028 ,  A61K31/155 ,  A61K31/396 ,  A61K31/10 ,  A61K31/4184 ,  A61K31/573 ,  A61K31/131 ,  A61K31/137 ,  A61K33/243 ,  A61K31/282 ,  A61P35/00 ,  A61K31/5386 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4375 ,  A61K31/5383 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/4985 ,  A61K31/422 ,  A61K31/506 ,  A61K31/438 ,  A61K31/537 ,  A61K31/635 ,  A61K31/541 ,  A61K47/54 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86

摘要： Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

公开(公告)号：US20220362182A1

公开(公告)日：2022-11-17

申请号：US17812126

申请日：2022-07-12

申请人： BRIGHTSEED, INC.

发明人： Lee Heil CHAE ,  Fred LEVINE

IPC分类号： A61K31/165 ,  A61K31/337 ,  A61K31/351 ,  A61K31/381 ,  A61K31/40 ,  A61K31/41 ,  A61K31/4409 ,  A61K31/277 ,  A61K31/167 ,  A61K31/4245 ,  A61P1/16

摘要： Disclosed herein are methods for reversing hepatic steatosis by providing a consumable composition. Some embodiments provided include, for example, administering a compound of Formula (I) or compound of Formula (II). Some embodiments provide the composition is formulated as a dietary supplement, food ingredient or additive, a medical food, nutraceutical or pharmaceutical composition.

公开(公告)号：US20220339153A1

公开(公告)日：2022-10-27

申请号：US17863642

申请日：2022-07-13

申请人： Kenneth Gek-Jin OOI ,  Stephanie Louise WATSON

发明人： Kenneth Gek-Jin OOI ,  Stephanie Louise WATSON

IPC分类号： A61K31/505 ,  A61K31/40 ,  A61K31/366 ,  A61K31/22 ,  A61K31/225 ,  A61K31/351 ,  A61K31/405 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/56 ,  A61K38/13

摘要： The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

公开(公告)号：US20220323400A1

公开(公告)日：2022-10-13

申请号：US17639831

申请日：2020-09-04

申请人： The Regents of the University of Michigan ,  WAYNE STATE UNIVERSITY

发明人： Yuqing Chen ,  Jifeng Zhang ,  Jie Xu ,  Xiubin Liang ,  Jian-Ping Jin ,  Fei Sun

IPC分类号： A61K31/351 ,  A61P11/00 ,  A61P3/10

摘要： This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of sodium-glucose cotransporter (SGLT) activity. The invention further relates to methods of treating and/or ameliorating symptoms related to cystic fibrosis (CF), comprising administering to a subject (e.g., a human patient) a composition comprising one or more pharmaceutical agents which function as inhibitors of SGLT activity.